{"entity":"bristol-myers-squibb","id":"ent_bristol-myers-squibb","name":"Bristol-Myers Squibb","wikidata":"Q266423","page":"https://asof.is/record/bristol-myers-squibb","summary":"Bristol-Myers Squibb is an American pharmaceutical company, headquartered in Princeton. Its CEO is Christopher S. Boerner, Ph.D, since 2023. It reported revenue of $48.30B for the period ended December 31, 2024.","title":null,"key_facts":[{"label":"CEO","value":"Christopher S. Boerner, Ph.D","note":"since 2023","claim":"clm_FF61856A3386"},{"label":"CFO","value":"David V. Elkins","claim":"clm_7B0B3B31B401"},{"label":"Headquarters","value":"Princeton","claim":"clm_C642296F0710"},{"label":"Revenue","value":"$48.30B","recorded":"48,300,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_78596CC18E60"},{"label":"Ticker","value":"BMY · NYSE","claim":"clm_ED7EF0279BF9"}],"faq":[{"question":"Who is the CEO of Bristol-Myers Squibb?","answer":"Christopher S. Boerner, Ph.D, since 2023, as the AsOf record states with its sources."},{"question":"Where is Bristol-Myers Squibb headquartered?","answer":"Princeton."},{"question":"What is Bristol-Myers Squibb's revenue?","answer":"$48.30B for the period ended December 31, 2024."}],"as_of":"2025-11-09","known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/bristol-myers-squibb/ceo","md":"https://asof.is/record/bristol-myers-squibb/ceo.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/ceo"},{"predicate":"chair","page":"https://asof.is/record/bristol-myers-squibb/chair","md":"https://asof.is/record/bristol-myers-squibb/chair.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/chair"},{"predicate":"cfo","page":"https://asof.is/record/bristol-myers-squibb/cfo","md":"https://asof.is/record/bristol-myers-squibb/cfo.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/cfo"},{"predicate":"headquarters","page":"https://asof.is/record/bristol-myers-squibb/headquarters","md":"https://asof.is/record/bristol-myers-squibb/headquarters.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/bristol-myers-squibb/revenue","md":"https://asof.is/record/bristol-myers-squibb/revenue.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/revenue"},{"predicate":"net_income","page":"https://asof.is/record/bristol-myers-squibb/net_income","md":"https://asof.is/record/bristol-myers-squibb/net_income.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/net_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/bristol-myers-squibb/quarterly_revenue","md":"https://asof.is/record/bristol-myers-squibb/quarterly_revenue.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/quarterly_revenue"}],"products":[],"coverage":{"entity":"bristol-myers-squibb","name":"Bristol-Myers Squibb","kind":"organization","sources":[{"source":"wikidata","item":"Q266423","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":14272,"ticker":"BMY","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":528,"open":25,"retracted":0,"first":"1989-01-01","predicates":{"total_assets":{"claims":71,"open":1,"kind":"fact"},"total_equity":{"claims":71,"open":1,"kind":"fact"},"shares_outstanding":{"claims":69,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":56,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":76,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"research_and_development":{"claims":19,"open":1,"kind":"fact"},"ticker":{"claims":2,"open":2,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"chair":{"claims":1,"open":1,"kind":"fact"},"website":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"cfo":{"claims":1,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":2,"open":1,"kind":"fact"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"ceo":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":526,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":2,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_8F913554EE54","predicate":"cash_and_equivalents","value":"15,726,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb cash and equivalents: 15,726,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_8F913554EE54, https://asof.is/claim/clm_8F913554EE54, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_8F913554EE54","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71B9DA11CD2A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_FF61856A3386","predicate":"ceo","value":"Christopher S. Boerner, Ph.D","valid_from":"2023-11-01","valid_to":null,"published":"2026-03-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb ceo: Christopher S. Boerner, Ph.D\", as of 2023-11-01. Claim clm_FF61856A3386, https://asof.is/claim/clm_FF61856A3386, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm.","url":"https://asof.is/claim/clm_FF61856A3386","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-25T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"Christopher S. Boerner, Ph.D. Board Chair & Chief Executive Officer of the Company Director Since: 2023 Age: 55 Board Committees • None Other Public Company Boards • Colgate-Palmolive Company Experience • Bristol Myers Squibb, Chief Executive Officer (November 2023-present)","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm"}},{"id":"clm_7B0B3B31B401","predicate":"cfo","value":"David V. Elkins","valid_from":null,"undated":true,"valid_to":null,"published":"2026-03-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb cfo: David V. Elkins\", undated. Claim clm_7B0B3B31B401, https://asof.is/claim/clm_7B0B3B31B401, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm.","url":"https://asof.is/claim/clm_7B0B3B31B401","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-25T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"David V. Elkins EVP and Chief Financial Officer Cristian Massacesi, M.D. EVP and Chief Medical Officer, Head of Development","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm"}},{"id":"clm_62358F2F8937","predicate":"chair","value":"Christopher S. Boerner, Ph.D","valid_from":"2024-04-01","valid_to":null,"published":"2026-03-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb chair: Christopher S. Boerner, Ph.D\", as of 2024-04-01. Claim clm_62358F2F8937, https://asof.is/claim/clm_62358F2F8937, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm.","url":"https://asof.is/claim/clm_62358F2F8937","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-25T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"Christopher S. Boerner, Ph.D. Board Chair & Chief Executive Officer of the Company Director Since: 2023 Age: 55 Board Committees • None Other Public Company Boards • Colgate-Palmolive Company Experience • Bristol Myers Squibb, Chief Executive Officer (November 2023-present) • Board Chair (April 2024","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm"}},{"id":"clm_772C4FAC73F0","predicate":"cik","value":"0000014272","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb cik: 0000014272\", undated. Claim clm_772C4FAC73F0, https://asof.is/claim/clm_772C4FAC73F0, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_772C4FAC73F0","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B055BC429569","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb fiscal year end: 12-31\", undated. Claim clm_B055BC429569, https://asof.is/claim/clm_B055BC429569, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_B055BC429569","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_C642296F0710","predicate":"headquarters","value":"Princeton","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb headquarters: Princeton\", undated. Claim clm_C642296F0710, https://asof.is/claim/clm_C642296F0710, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_C642296F0710","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7C0328B0E90C","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb listed on: NYSE\", undated. Claim clm_7C0328B0E90C, https://asof.is/claim/clm_7C0328B0E90C, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_7C0328B0E90C","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_93176D9F8458","predicate":"net_income","value":"-8,948,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb net income: -8,948,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_93176D9F8458, https://asof.is/claim/clm_93176D9F8458, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm.","url":"https://asof.is/claim/clm_93176D9F8458","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_52D44073C808","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-12"}},{"id":"clm_B6387AF1FB92","predicate":"quarterly_net_income","value":"2,201,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb quarterly net income: 2,201,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_B6387AF1FB92, https://asof.is/claim/clm_B6387AF1FB92, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_B6387AF1FB92","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_59B16D5CFE58","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_B92B3F0BD51E","predicate":"quarterly_operating_income","value":"1,402,000,000 United States dollar","valid_from":"2012-03-31","valid_to":null,"published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb quarterly operating income: 1,402,000,000 United States dollar\", as of 2012-03-31. Claim clm_B92B3F0BD51E, https://asof.is/claim/clm_B92B3F0BD51E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000119312512184689/0001193125-12-184689-index.htm.","url":"https://asof.is/claim/clm_B92B3F0BD51E","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000119312512184689/0001193125-12-184689-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-04-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2012, filed 2012-04-26"}},{"id":"clm_F60212FAE72C","predicate":"quarterly_research_and_development","value":"2,528,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb quarterly research and development: 2,528,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_F60212FAE72C, https://asof.is/claim/clm_F60212FAE72C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_F60212FAE72C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_66E70FD09231","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_BB784B853512","predicate":"quarterly_revenue","value":"12,222,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb quarterly revenue: 12,222,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_BB784B853512, https://asof.is/claim/clm_BB784B853512, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_BB784B853512","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3BBDC1786FBC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_B021E66EA136","predicate":"registrant_name","value":"BRISTOL MYERS SQUIBB CO","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb registrant name: BRISTOL MYERS SQUIBB CO\", undated. Claim clm_B021E66EA136, https://asof.is/claim/clm_B021E66EA136, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_B021E66EA136","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_CC290D20ACB7","predicate":"research_and_development","value":"11,159,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb research and development: 11,159,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_CC290D20ACB7, https://asof.is/claim/clm_CC290D20ACB7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm.","url":"https://asof.is/claim/clm_CC290D20ACB7","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1D1D9926921B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2024, filed 2025-02-12"}},{"id":"clm_78596CC18E60","predicate":"revenue","value":"48,300,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb revenue: 48,300,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_78596CC18E60, https://asof.is/claim/clm_78596CC18E60, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm.","url":"https://asof.is/claim/clm_78596CC18E60","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BB9F55DFC7A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-12"}},{"id":"clm_5DF65CC84443","predicate":"shares_outstanding","value":"2,035,753,027 shares","valid_from":"2025-10-23","valid_to":"2026-02-04","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb shares outstanding: 2,035,753,027 shares\", as of 2025-10-23 (until 2026-02-04). Claim clm_5DF65CC84443, https://asof.is/claim/clm_5DF65CC84443, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_5DF65CC84443","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7BDDFBA6A82F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_DF7B0F2F37F6","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_DF7B0F2F37F6, https://asof.is/claim/clm_DF7B0F2F37F6, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_DF7B0F2F37F6","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_48211D1EBA75","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb state of incorporation: DE\", undated. Claim clm_48211D1EBA75, https://asof.is/claim/clm_48211D1EBA75, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_48211D1EBA75","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_ED7EF0279BF9","predicate":"ticker","value":"BMY","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb ticker: BMY\", undated. Claim clm_ED7EF0279BF9, https://asof.is/claim/clm_ED7EF0279BF9, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_ED7EF0279BF9","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_1EFB3D1960DA","predicate":"ticker","value":"CELG-RI","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb ticker: CELG-RI\", undated. Claim clm_1EFB3D1960DA, https://asof.is/claim/clm_1EFB3D1960DA, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_1EFB3D1960DA","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B080F3CCA436","predicate":"total_assets","value":"96,889,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb total assets: 96,889,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_B080F3CCA436, https://asof.is/claim/clm_B080F3CCA436, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_B080F3CCA436","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_16735433DCF9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_3AA608585C53","predicate":"total_equity","value":"18,552,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb total equity: 18,552,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_3AA608585C53, https://asof.is/claim/clm_3AA608585C53, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_3AA608585C53","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D808E9CABB64","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_6C58446D45ED","predicate":"website","value":"https://www.bms.com/","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb website: https://www.bms.com/\", undated. Claim clm_6C58446D45ED, https://asof.is/claim/clm_6C58446D45ED, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q266423.","url":"https://asof.is/claim/clm_6C58446D45ED","accessed":"2026-11-09"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Bristol Myers Squibb - Global Biopharmaceutical Company.","url":"https://www.bms.com/"}},{"id":"clm_7954DAE3098C","predicate":"x_username","value":"bmsnews","valid_from":"2009-04-21","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb x username: bmsnews\", as of 2009-04-21. Claim clm_7954DAE3098C, https://asof.is/claim/clm_7954DAE3098C, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q266423.","url":"https://asof.is/claim/clm_7954DAE3098C","accessed":"2026-11-09"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/BMSNEWS","url":"https://www.bms.com/"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}